QuiverFullPill Fact Sheet

Fact Sheet - Contraceptive Pill Side-Effects

1) Breast Cancer

Therefore the range these studies cite for breast cancer is 200-820%

(Note: With use of Depo-Provera (DMPA) - "Use for two years or longer before age 25 was associated with a significantly increased risk of breast cancer" (ie 360% increase) (6) *p100

2) Cervical Cancer

3) Deep Vein Thrombosis (DVT)

4) Infertility after pill-use

5) Teratogenicity

Fertility drugs cause hyperstimulation of the ovaries, leading to increased ovarian cancer of the ovary due to increased minor trauma of the covering epilthelium *p141
The pill, and pregnancy, and breast feeding cause a rest in ovulation, thus associated with a decreased incidence of ovarian cancer. Some family planning advocates defend or advocate pill use because of the associated decrease in ovarian cancer rates(0.2% risk). To do so in light of the magnitude of the side-effects of the pill documented is a woeful ignorance of the facts or a deliberate and cynical act of injustice to women.

All references from - A Consumer's Guide to the Pill by John Wilks B Pharm
MPS 2nd Ed1997 ALL Publications
Available from HLI (Ireland) £14 which includes p & p


1) Olsson H, Borg A, Ferno M, Moller TR, Ranstam J. Early oral contraceptive use and premenopausal breast cancer - a review of studies performed in South Sweden Cancer Detection and Prevention 1991:15 (4): 265-271 Table IV.
2) Olsson H & ML, Moller TR, Ranstam J, Holm P. Lancet(letter) 1985 March 30, 748-49
3) Olsson H, Moller TR, Ranstam J. Early oral contraceptive use and breast cancer among premenopausal women: Final report from a study in Southern Sweden. Journal of the National Cancer Institute. 1989;81(12):1000-4
4) Johnson JH, Weighing the evidence on the pill and breast cancer Family Planning Perspectives 1989: 21 (2): 89-92
4a) Rookus & Van Leeuwen. Oral Contraceptives and risk of Breast Cancer women aged 20-54 years. Lancet 1994 ; 344; p844-51
4b) Millar DR, Rosenberg L, et al Breast Cancer before age 45 and oral
contraceptive use ; new findings. American J of Epidemiology 1989;129
(2):269- 80,
5) Olsson H, Borg A, ferno M, Moller T, Ranstam J. Early oral contraceptive use and breast cancer in Southern Sweden. Proc. Annu Meet Am Soc Clin Oncol. 1989: A367, Ma
5a) WHO Cancer Mortality database 1994 Breast Cancer Rates by Country.
6) Paul C, Depo medroxyprogesterone (Depo-Provera) and risk of breast cancer Br Med J 1989; 299: p762
7) Thomas DB, Ray RM. Oral contraceptives and invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix Am J Epid 1996;144:p284 table 2.,
8) Kohler U, Wuttke P. results of a case control study of the current effect of various factors of cervical cancer risk . 2) Contraceptive behaviour and the smoking factor. Zentralblatt fur gynakologie 1994;116 (7): 405- 9 (Ma)
9) Ursin G, Peters RK, Henderson BE, d'Ablaing G, Monroe KR, Pike MC. Oral contraceptive use and adenocarcinoma of cervix. Lancet 1994; 344; 1390-1394
10) Brisson J et al Risk factors for cervical Intraepithelial Neoplasia: differences between low and high-grade lesions American J of Epidemiology 1994;140:700-710
11) Chen Y-H, Huang L-H, Chen T-M. Differential effects of progestins and estrogens on long control regions of human papilloma virus types 16 and 18. Biochemical and Biophysical Research Communications 1996;224:p654
12) Kenney JAW. Risk Factors associated with genital HPV infection. Cancer Nurse 1996 (Oct);19:5, p353
13) Vandebrouke JP, Rosendaal FR. End of the line for "third-generation pill" controversy? Lancet 1997; 349:1113-1114
14) Vandenbrouke JP et al Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:p 1454
15) Bloemenkamp KW, Rosendal FR, Helmerhorst FM, Bauller HR, Vandenbroche JP. Enhancement by factor V Leiden mutation of deep vein thrombosis associated with oral contraceptives containing third generation progestogen. Lancet 1995;346:8990:1593-6
16) Ref 15 p1594, table 1
17) Spitzer WO, Lewis MA, Heineman LAJ et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study Br Med J 1996;312:83-8
18) Bloemenkamp et al p1595
19) APPG 24th Ed Microgynon 30 monograph 1995 p1508
20) Micromedex vol 89 Oral contraceptives monograph
21) Wade ME, McCarthy PM et al. Am J Obstet Gynaecol 1995; 172: p698
22) Rahwan R, Prof Pharmacology & Toxicology, College of Pharmacy Ohio State University. Chemical Contraceptives, Interceptives and Abortifacients 1995